Avicenna Biosciences, Inc.

Avicenna Biosciences has developed a machine learning-driven medicinal chemistry platform that accelerates the optimization of small molecule drug candidates. The company has achieved rapid progression from idea to in vivo proof-of-concept and initiated IND-enabling studies for its CNS-targeted ROCK inhibitor program within about one year. Its approach enables discovery with fewer compounds and lower costs compared to traditional methods. The company recently secured a U.S. patent for novel neurodegeneration-targeting compounds and published collaborative research with Schrödinger and Microsoft Research AI4Science demonstrating the efficiency of their technology.

In July 2024, Avicenna entered a strategic collaboration with Molecure S.A. to develop USP7 inhibitors for oncology.

Pipeline breadth includes at least five preclinical or early-stage programs targeting neurodegeneration and cancer.

No clinical results have been reported yet; most assets are preclinical or at IND-enabling stages.

Funding raised totals $20.5 million as of late 2023/early 2024.

Key partnerships include Molecure S.A., Schrödinger, Microsoft Research AI4Science.

Founders are Drs. Thomas Kaiser and Pieter Burger from Emory University’s Liotta Research Group; CEO Christopher Meldrum joined from DCVC Bio.

Headquarters location not explicitly stated but likely US-based given founders’ affiliations.

Not related to similarly named companies such as Avicanna or Avicenna Oncology GmbH.